Food and Drug Administration (FDA) Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Molecular insights into clinical trials for immune checkpoint inhibitors in colorectal cancer: Unravelling challenges and future directions
World J Gastroenterol. 2024 Apr 7;30(13):1815-1835. doi: 10.3748/wjg.v30.i13.1815.ABSTRACTColorectal cancer (CRC) is a complex disease with diverse etiologies and clinical outcomes. Despite considerable progress in development of CRC therapeutics, challenges remain regarding the diagnosis and management of advanced stage metastatic CRC (mCRC). In particular, the five-year survival rate is very low since mCRC is currently rarely curable. Over the past decade, cancer treatment has significantly improved with the introduction of cancer immunotherapies, specifically immune checkpoint inhibitors. Therapies aimed at blocking imm...
Source: World Journal of Gastroenterology : WJG - April 25, 2024 Category: Gastroenterology Authors: Samantha Sharma Naresh Singh Anita Ahmed Turk Isabella Wan Akshay Guttikonda Julia Lily Dong Xinna Zhang Mateusz Opyrchal Source Type: research

Biomedical Approaches and Disparities in HIV Prevention
Human immunodeficiency virus (HIV) remains a significant public concern, with certain groups disproportionately impacted. Pre-exposure prophylaxis (PrEP) for HIV prevention was approved by the Food and Drug Administration in 2012. However, stark disparities persist in PrEP access and uptake, leaving those at highest risk of acquiring HIV without knowledge of, access to, and uptake of PrEP. Nurses play a key role in eliminating the causes of these disparities that occur at the individual, provider, and systemic level. It is imperative that we increase PrEP knowledge, access, and use, especially in groups most at risk for ac...
Source: Nursing Clinics of North America - April 25, 2024 Category: Nursing Authors: Jared Carter-Davis, Ellen Seymour Source Type: research

Cancers, Vol. 16, Pages 1643: Prostate-Specific Membrane Antigen-Targeted Therapy in Prostate Cancer: History, Combination Therapies, Trials, and Future Perspective
Francesco Ceci In the last decades, the development of PET/CT radiopharmaceuticals, targeting the Prostate-Specific Membrane Antigen (PSMA), changed the management of prostate cancer (PCa) patients thanks to its higher diagnostic accuracy in comparison with conventional imaging both in staging and in recurrence. Alongside molecular imaging, PSMA was studied as a therapeutic agent targeted with various isotopes. In 2021, results from the VISION trial led to the Food and Drug Administration (FDA) approval of [177Lu]Lu-PSMA-617 as a novel therapy for metastatic castration-resistant prostate cancer (mCRPC) and set the ba...
Source: Cancers - April 25, 2024 Category: Cancer & Oncology Authors: Francesco Mattana Lorenzo Muraglia Antonio Barone Marzia Colandrea Yasmina Saker Diffalah Silvia Provera Alfio Severino Cascio Emanuela Omodeo Sal è Francesco Ceci Tags: Review Source Type: research

Serious neurological adverse events in immunocompetent children and adolescents caused by viral reactivation in the years following varicella vaccination
Rev Med Virol. 2024 May;34(3):e2538. doi: 10.1002/rmv.2538.ABSTRACTSerious adverse events following vaccination include medical complications that require hospitalisation. The live varicella vaccine that was approved by the Food and Drug Administration in the United States in 1995 has an excellent safety record. Since the vaccine is a live virus, adverse events are more common in immunocompromised children who are vaccinated inadvertently. This review includes only serious adverse events in children considered to be immunocompetent. The serious adverse event called varicella vaccine meningitis was first reported in a hospi...
Source: Herpes - April 24, 2024 Category: Infectious Diseases Authors: Prashanth Ramachandran Charles Grose Source Type: research

Food and Drug Omnibus Reform Act: A Critical Course Correction
On December 29, 2022, the Consolidated Appropriations Act, 2023 (Public Law No. 117-328) was signed into law, containing the Food and Drug Omnibus Reform Act of 2022 (FDORA), which introduces significant reforms to the US Food and Drug Administration (FDA).1 This paper highlights select provisions of FDORA that, in our view, have broad implications for the clinical and pharmaceutical sectors, such as promoting clinical trial diversity, revising the accelerated approval process, modernizing clinical trial operations, updating marketing exclusivities, expanding cosmetics regulation, and fortifying infant formula oversight. (...
Source: Mayo Clinic Proceedings - April 24, 2024 Category: Internal Medicine Authors: Aditya Narayan, I. Glenn Cohen, Eli Y. Adashi Tags: Perspectives and controversies Source Type: research

Reduction of product composition variability using pooled microbiome ecosystem therapy and consequence in two infectious murine models
In this study, we compared the metagenomic profile of pooled products to corresponding single donor-derived products. We demonstrated that pooled products are more homogeneous, diverse, and enriched in beneficial bacteria known to produce anti-inflammatory short chain fatty acids compared to single donor-derived products. We then evaluated pooled products' efficacy compared to corresponding single donor-derived products in Salmonella and C. difficile infectious mouse models. We were able to demonstrate that pooled products decreased pathogenicity by inducing a structural change in the intestinal microbiota composition. Sin...
Source: Cancer Control - April 23, 2024 Category: Cancer & Oncology Authors: Julie Reygner Johanne Delannoy Marie-Th érèse Barba-Goudiaby Cyrielle Gasc Beno ît Levast Enora Gaschet Laurent Ferraris St éphane Paul Nathalie Kapel Anne-Judith Waligora-Dupriet Frederic Barbut Muriel Thomas Carole Schwintner Bastien Laperrousaz Nat Source Type: research

Reduction of product composition variability using pooled microbiome ecosystem therapy and consequence in two infectious murine models
In this study, we compared the metagenomic profile of pooled products to corresponding single donor-derived products. We demonstrated that pooled products are more homogeneous, diverse, and enriched in beneficial bacteria known to produce anti-inflammatory short chain fatty acids compared to single donor-derived products. We then evaluated pooled products' efficacy compared to corresponding single donor-derived products in Salmonella and C. difficile infectious mouse models. We were able to demonstrate that pooled products decreased pathogenicity by inducing a structural change in the intestinal microbiota composition. Sin...
Source: Applied and Environmental Microbiology - April 23, 2024 Category: Microbiology Authors: Julie Reygner Johanne Delannoy Marie-Th érèse Barba-Goudiaby Cyrielle Gasc Beno ît Levast Enora Gaschet Laurent Ferraris St éphane Paul Nathalie Kapel Anne-Judith Waligora-Dupriet Frederic Barbut Muriel Thomas Carole Schwintner Bastien Laperrousaz Nat Source Type: research

Exploring the role of histone deacetylase and histone deacetylase inhibitors in the context of multiple myeloma: mechanisms, therapeutic implications, and future perspectives
AbstractHistone deacetylase inhibitors (HDACis) are a significant category of pharmaceuticals that have developed in the past two decades to treat multiple myeloma. Four drugs in this category have received approval from the U.S. Food and Drug Administration (FDA) for use: Panobinonstat (though canceled by the FDA in 2022), Vorinostat, Belinostat and Romidepsin. The efficacy of this group of drugs is attributed to the disruption of many processes involved in tumor growth through the inhibition of histone deacetylase, and this mode of action leads to significant anti-multiple myeloma (MM) activity. In MM, inhibition of hist...
Source: Experimental Hematology and Oncology - April 23, 2024 Category: Cancer & Oncology Source Type: research

Stilbenes: a journey from folklore to pharmaceutical innovation
Arch Microbiol. 2024 Apr 22;206(5):229. doi: 10.1007/s00203-024-03939-z.ABSTRACTIn modern times, medicine is predominantly based on evidence-based practices, whereas in ancient times, indigenous people relied on plant-based medicines with factual evidence documented in ancient books or folklore that demonstrated their effectiveness against specific infections. Plants and microbes account for 70% of drugs approved by the USFDA (U.S. Food and Drug Administration). Stilbenes, polyphenolic compounds synthesized by plants under stress conditions, have garnered significant attention for their therapeutic potential, bridging anci...
Source: Archives of Microbiology - April 22, 2024 Category: Microbiology Authors: Gursharan Kaur Rajinder Kaur Gurleen Kaur Sodhi Nancy George Santosh Kumar Rath Harleen Kaur Walia Vagish Dwibedi Sanjai Saxena Source Type: research

Electronic cigarettes: beneficial for smoking cessation but harmful to public health?
This study is a step toward addressing that uncertainty about how e-cigarettes could be used to promote smoking cessation among... (Source: Emergency Medicine Journal)
Source: Emergency Medicine Journal - April 22, 2024 Category: Emergency Medicine Authors: Kruse, G., Samet, J., Barnoya, J. Tags: Press releases Commentary Source Type: research

Effect of Hepatic Impairment on Trilaciclib Pharmacokinetics
J Clin Pharmacol. 2024 Apr 19. doi: 10.1002/jcph.2435. Online ahead of print.ABSTRACTTrilaciclib is a first-in-class, intravenous cyclin-dependent kinase 4 and 6 inhibitor approved for reducing the incidence of chemotherapy-induced myelosuppression in adult patients with extensive-stage small cell lung cancer receiving a platinum/etoposide-containing or topotecan-containing regimen. No dose adjustment is recommended for participants with mild hepatic impairment (HI) based on previous population pharmacokinetic (PK) analysis. This open-label, parallel-group study examined the impact of moderate and severe HI on the PK of tr...
Source: The Journal of Clinical Pharmacology - April 19, 2024 Category: Drugs & Pharmacology Authors: Chao Li Richard A Preston Emily Dumas Andrew Beelen Thomas C Marbury Source Type: research

Effect of Hepatic Impairment on Trilaciclib Pharmacokinetics
J Clin Pharmacol. 2024 Apr 19. doi: 10.1002/jcph.2435. Online ahead of print.ABSTRACTTrilaciclib is a first-in-class, intravenous cyclin-dependent kinase 4 and 6 inhibitor approved for reducing the incidence of chemotherapy-induced myelosuppression in adult patients with extensive-stage small cell lung cancer receiving a platinum/etoposide-containing or topotecan-containing regimen. No dose adjustment is recommended for participants with mild hepatic impairment (HI) based on previous population pharmacokinetic (PK) analysis. This open-label, parallel-group study examined the impact of moderate and severe HI on the PK of tr...
Source: Clinical Lung Cancer - April 19, 2024 Category: Cancer & Oncology Authors: Chao Li Richard A Preston Emily Dumas Andrew Beelen Thomas C Marbury Source Type: research

Themes in e-liquid concept names as a marketing tactic: evidence from Premarket Tobacco Product Applications in the USA
Concept naming of flavours is popular among e-liquid manufacturers.1–3 Rather than explicitly stating a taste or smell, these names convey aesthetics or sensations (eg, unicorn, frostbite, roadhouse), as well as positive health and lifestyle experiences (eg, relaxed, blissful).4 Concept names are frequently accompanied by colourful packaging and bottle designs that reinforce their connotations.1 2 While concept naming is not novel, its impact on youth appeal, as distinct from the flavours themselves, is understudied.5 Concept naming warrants additional attention following US regulatory developments limiting character...
Source: Tobacco Control - April 19, 2024 Category: Respiratory Medicine Authors: Laestadius, L., Vassey, J., Kim, M., Ozga, J., Li, D., Stanton, C., Wipfli, H., Unger, J. B. Tags: Open access Industry watch Source Type: research